World Health Organization site
Skip Navigation Links

Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 17 October 2012
Main ID:  NCT01019473
Date of registration: 19/11/2009
Primary sponsor: Novartis Pharmaceuticals
Public title: Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea
Scientific title: A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing Chorea
Date of first enrolment: November 2009
Target sample size: 44
Recruitment status: Terminated
Study type:  Interventional
Study design:  Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment  
Countries of recruitment
Key inclusion & exclusion criteria

Inclusion Criteria:

- Huntington's disease (based on DNA testing polyQ >36) with a UHDRS maximal chorea
score of >10

- patient with concomitant Huntington's medication (anti-depressants, neuroleptics,
benzodiazepines) are allowed but the total daily dose and dosing regimen has to be
stable for at least one months prior to randomization

- female patients without childbearing potential (post-menopausal or surgically
sterilized), all patients must using a double-barrier local contraception

Exclusion Criteria:

- patients with marked cognitive impairment (MMSE less than 18), with presence of
psychosis and/or confusional states

- patients with a history or presence of renal impairment and/or liver disease Other
protocol-defined inclusion/exclusion criteria may apply

Age minimum: 30 Years
Age maximum: 85 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Huntington's Disease
Drug: AFQ056
Drug: Placebo
Primary Outcome(s)
Efficacy of AFQ056 on the severity of chorea in Huntington's disease measured by Unified Huntington's Disease Rating Scale (UHDRS) Maximal Chorea score. [Time Frame: Baseline to day 28]
Secondary Outcome(s)
Potential effect of AFQ056 on functional and quality of life scales, neuropsychiatric assessments and cognitive assessments in Huntington's Disease patients [Time Frame: Day 1 to day 46]
Potential effect of AFQ056 on the motor, cognitive, behavioral and functional assessments using UHDRS. [Time Frame: Day 1 to day 46]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history